Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.
[PURPOSE] This study aimed to evaluate the feasibility of the Repeatable Microcatheter-accessible Port (ReMAP™) system in initial clinical experiences.
APA
Tanaka T, Sato T, et al. (2026). Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.. Interventional radiology (Higashimatsuyama-shi (Japan), 11, e20250077. https://doi.org/10.22575/interventionalradiology.2025-0077
MLA
Tanaka T, et al.. "Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.." Interventional radiology (Higashimatsuyama-shi (Japan), vol. 11, 2026, pp. e20250077.
PMID
41878396
Abstract
[PURPOSE] This study aimed to evaluate the feasibility of the Repeatable Microcatheter-accessible Port (ReMAP™) system in initial clinical experiences.
[MATERIAL AND METHODS] Eighteen patients with advanced hepatocellular carcinoma underwent ReMAP™ implantation. The 3.3-Fr catheter tip was positioned in the hepatic, gastroduodenal, or splenic artery, with the side hole located in the common or proper hepatic artery. The 6-Fr proximal end of the catheter was connected to the ReMAP™ device, implanted subcutaneously in the front thigh. A specialized 17-G cannulated needle was used to puncture the ReMAP™ system, allowing insertion of a microcatheter and guidewire, which exited via the side hole and were advanced into the targeted hepatic branches.
[RESULTS] ReMAP™ implantation was successful in all cases. A total of 85 treatment sessions using microcatheters inserted via the ReMAP™ system were performed. All sessions successfully facilitated selective arterial infusion chemotherapy (75 sessions) and selective transarterial chemoembolization (10 sessions). During the treatment period (mean duration: 4.6 months), complications occurred in three cases (18%), including hepatic arterial occlusion, dislocation of the indwelling catheter, and biloma.
[CONCLUSIONS] Locoregional treatments using the ReMAP™ system are feasible for patients with advanced hepatocellular carcinoma.
[MATERIAL AND METHODS] Eighteen patients with advanced hepatocellular carcinoma underwent ReMAP™ implantation. The 3.3-Fr catheter tip was positioned in the hepatic, gastroduodenal, or splenic artery, with the side hole located in the common or proper hepatic artery. The 6-Fr proximal end of the catheter was connected to the ReMAP™ device, implanted subcutaneously in the front thigh. A specialized 17-G cannulated needle was used to puncture the ReMAP™ system, allowing insertion of a microcatheter and guidewire, which exited via the side hole and were advanced into the targeted hepatic branches.
[RESULTS] ReMAP™ implantation was successful in all cases. A total of 85 treatment sessions using microcatheters inserted via the ReMAP™ system were performed. All sessions successfully facilitated selective arterial infusion chemotherapy (75 sessions) and selective transarterial chemoembolization (10 sessions). During the treatment period (mean duration: 4.6 months), complications occurred in three cases (18%), including hepatic arterial occlusion, dislocation of the indwelling catheter, and biloma.
[CONCLUSIONS] Locoregional treatments using the ReMAP™ system are feasible for patients with advanced hepatocellular carcinoma.
같은 제1저자의 인용 많은 논문 (5)
- Computed Tomography Findings of Pulmonary Lymphoma in a Dog and Two Cats.
- Carbon fiber-reinforced polyetheretherketone spinal instrumentation in pediatric spinal tumors: report of two cases and review of the literature.
- Variations in liver allocation systems across continents with a focus on MELD exceptions.
- Association between Microbiome Dysbiosis and Postoperative Disorders before and after Gastrectomy.
- Safety and feasibility of laparoscopic stomach-partitioning gastrojejunostomy combined with neoadjuvant chemotherapy followed by minimally invasive gastrectomy for resectable gastric cancer with gastric outlet obstruction.